We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
CytoSorbents Corporation (NASDAQ: CTSO) is a critical care immunotherapy company commercializing its CytoSorb blood purification technology in 53 countries worldwide to treat deadly inflammation in life-threatening conditions in the ICU (such as sepsis, trauma, burn injury, liver disease, lung injury, pancreatitis and many others) and cardiac surgery. CytoSorb has garnered more than 51,000 human treatments cumulatively as a "razorblade disposable" that is compatible with existing blood pumps in the hospital, with $19.1M in trailing 12-month sales and healthy 72% blended gross margins. 4 major partners: Fresenius Medical Care, Terumo Cardiovascular, Biocon and Dr. Reddys. $25M+ in U.S. grant funding.